Objective: Carotid artery stenting (CAS) is a less invasive alternative to carotid endarterectomy, but it is essential to prevent thromboembolic complications during CAS and to suppress in-stent restenosis (ISR) after CAS because of the relatively high risk of periprocedural and follow-up stroke events. Clinical trials have demonstrated the strong relationship of carotid plaque vulnerability with the subsequent risk of ipsilateral ischemic stroke and thromboembolic complications during CAS. Recent studies demonstrated that both low eicosapentaenoic acid (EPA) and low docosahexaenoic acid (DHA) levels were significantly associated with lipid-rich coronary and carotid plaques, but little is known about the effect of administration of omega-3 fatty acids (O-3FAs) containing EPA and DHA before and after CAS for stabilizing carotid plaque, preventing thromboembolic complications, and suppressing ISR. In this study, the efficacy of pretreatment with and ongoing daily use of O-3FA in addition to statin treatment was evaluated in patients undergoing CAS.
Carotid artery stenosis is a major risk factor for ischemic stroke. Although carotid endarterectomy has been the "gold standard" for primary and secondary stroke prevention, a randomized trial, the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), showed no differences in stroke, myocardial infarction, or death during the periprocedural period between carotid artery stenting (CAS) and carotid endarterectomy. 1 CAS is currently becoming widely performed as a less invasive alternative to carotid endarterectomy. However, CREST also demonstrated that CAS patients had a higher incidence of periprocedural stroke than patients treated with carotid endarterectomy. Therefore, in carotid artery stenosis patients undergoing CAS, it is essential to prevent thromboembolic complications during CAS. Clinical trials have demonstrated the strong relationship of carotid plaque echolucency with the histologic contents of vulnerable carotid plaque and the subsequent risk of ipsilateral ischemic stroke, 2 and recent advances in plaque imaging techniques have provided preoperative information about vulnerable plaque that might readily cause distal embolism. Thromboembolic complications during CAS were reportedly more often observed in patients with symptomatic echolucent plaque, 3 From the Department of Neurosurgery a and Department of Radiology, b Nara
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Copyright fibrofatty plaque volume on virtual histology intervascular ultrasound (VH-IVUS), 4 or high-intensity signals in the plaques detected by black-blood magnetic resonance imaging (MRI). 5 Stabilization of echolucent carotid plaques by statin treatment has been reported in the literature, 6, 7 and statin pretreatment reduced the frequency of periprocedural ischemic complications with CAS. 8 However, it has not been shown that statin treatment can prevent periprocedural thromboembolic complications during CAS. On the other hand, in-stent restenosis (ISR) after CAS is associated with an increased risk of ipsilateral stroke. Recent studies demonstrated that hypertension and impaired cerebrovascular reactivity are predictors of ISR after CAS, 9 but how to prevent ISR remains unclear.
It is widely accepted that intake of fish and fish oil protects against cardiovascular diseases, atherosclerosis, and stroke. 10 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the major omega-3 fatty acids (O-3FAs) contained in fish oil, show anti-inflammatory effects and reduction of platelet aggregation and plasma triglycerides. A lower serum EPA level is associated with a greater risk of cardiovascular disease in the general Japanese population, 11 and studies have demonstrated that both low EPA and low DHA levels are significantly associated with lipid-rich coronary plaque 12 and atherosclerotic carotid plaque, 13 suggesting their contribution to the incidence of acute coronary syndrome or symptomatic carotid artery stenosis. However, little is known about the effect of administration of O-3FAs before and after CAS for stabilization of carotid plaque and for prevention of ISR. In this study, the efficacy of pretreatment with and ongoing daily use of O-3FAs in combination with statin treatment was evaluated in patients undergoing CAS.
METHODS
Inclusion criteria of patients. A total of 100 consecutive patients who suffered from hyperlipidemia undergoing CAS for carotid artery stenosis at Nara Medical University were recruited from January 2012 to May 2015. The criteria used for CAS included stenosis >80% for asymptomatic lesions or stenosis >50% for symptomatic lesions and patients having a high risk for carotid endarterectomy in accordance with the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) criteria. 14 
Recommendation:
The data suggest that pretreatment with omega-3 fatty acids may have a beneficial effect in reducing the incidence of in-stent restenosis after carotid artery stenting.
to at least 12 months after CAS. All patients signed a written authorization allowing access to their medical records for research purposes, and our Institutional Review Board approved the research protocol (No. 1140). All patients were given an informed consent document that explained all of the CAS procedures, and they provided their written, informed consent.
Interventional procedure. During the CAS procedure, which was performed under local anesthesia, intravenous heparin was used to maintain an activated clotting time of >275 seconds. An 8F guiding catheter was first placed in the common carotid artery. After crossing of the stenotic lesion with a guidewire, a filter-type embolic protection device (FilterWire EZ; Stryker, Kalamazoo, Mich) was inserted distal to the stenotic lesion. Using angioplasty balloons with diameters no greater than approximately 80% of the normal luminal diameter distal to the stenosis, conservative postdilation was then performed. The procedure was monitored through the use of intravascular ultrasound (Eagle Eye Gold; Volcano Corporation, San Diego, Calif). VH-IVUS was recorded to analyze carotid plaque characteristics before stent placement. At the end of the procedure, the embolic protection device was removed. We evaluated the blood flow decrease in the internal carotid artery during the procedure, and slow-flow phenomenon was defined as an angiographically significant reduction in antegrade flow in the internal carotid artery compared with the external carotid artery. An aspiration catheter was used to perform multiple aspirations of the column of blood proximal to the filter when a slow-flow phenomenon was observed. During follow-up of the patients, all symptomatic ischemic events, hemorrhagic events within 30 days, slow-flow phenomenon, antiplatelet resistance, and any diffusion-weighted MRI abnormalities that occurred were recorded. ISR after CAS was also evaluated using ultrasound at 12-month follow-up intervals.
Serum lipid and fatty acid analysis. Fasting blood samples were collected through venipuncture. All samples were collected at the same three time points: 4 weeks before CAS, a day before CAS, and 3 months after CAS. Serum fatty acid fractions (DHA, EPA, and arachidonic acid [AA]) were examined. Contents of total lipids were analyzed by capillary gas chromatography, and the DHA/AA and EPA/AA ratios were calculated.
Diffusion-weighted MRI evaluation and MRI plaque imaging. A 3T system (Verio; Siemens, Erlangen, Germany) with a multisection, single-shot, spin-echo planar imaging sequence was used to perform the diffusion-weighted imaging (DWI) 1 day after the procedure. The imaging parameters included the following: echo time, 100 milliseconds; field of view, 23 cm; intersection gap, 1 mm; matrix, 96 Â 128; and section thickness, 5 mm. Apparent diffusion coefficient maps were obtained in all cases, with experienced neuroradiologists who were blinded to the clinical information reviewing all of the DWI scans and apparent diffusion coefficient maps. Procedure-related cerebral embolism-caused ischemic lesions were defined as any new ipsilateral hyperintense lesion observed on DWI. MRI for plaque characterization was also performed on a 3T system (Verio). A two-dimensional T1-weighted fast spin-echo sequence was performed 4 weeks before CAS using a black-blood double inversion recovery preparation pulse and a fat-saturation pulse. The signal intensities were measured with the region of interest drawn over the carotid plaque at the most severely stenotic level. The signal intensity ratio of the plaque relative to adjacent muscle was calculated, and unstable plaque was defined as >1.5, according to a previous report. 15 VH-IVUS and ultrasound surveillance. IVUS images were analyzed using Volcano Imaging Analysis Software (Volcano Corporation) to determine plaque composition and morphology. Vessel and lumen borders were manually corrected and agreed on by two different readers for each patient. Plaque composition data were automatically generated by the software and included lumen and vessel areas, minimal lumen and vessel diameters, plaque burden, media area, and plaque tissue area (necrotic, fibrous, fibrofatty, and calcified). Plaque composition was determined by averaging virtual histology data from a minimum of 10 frames surrounding the area of highest stenosis. 16 A follow-up ultrasound examination was performed 3, 6, and 12 months after CAS. All ultrasound examinations were performed in the same laboratory using a duplex ultrasound machine (Aplio 500; Toshiba Medical Systems, Tokyo, Japan). Ultrasound grading of carotid ISR needs customized validated criteria because the standard velocity criteria used for nonstented carotid arteries are inappropriate. ISR was determined according to established criteria for duplex ultrasound imaging. 17 ISR was defined as peak systolic velocity (PSV) >170 cm/s because PSV >170 cm/s was indicative of a >50% diameter stenosis. Percutaneous balloon angioplasty for re-treatment was performed in patients who showed PSV >300 cm/s, which was indicative of a >70% diameter stenosis.
Statistical analysis. All data are presented as means 6 standard deviation. Differences between the two periods were assessed using Fisher exact test. The patients' age was compared between the two periods using MannWhitney U test. Serum lipid and fatty acid values were assessed by repeated-measures analysis of variance. Univariate analysis was performed, and factors with a P value < .10 were included in the multivariate logistic regression analysis. Significance was considered at a P value < .05. Table I presents the clinical characteristics of the patients from the two different periods. This study enrolled and evaluated a total of 100 patients (85 men and 15 women; mean age, 74 years). For the control period (47 patients), the mean age was 72 years (range, 58-86 years); for the O-3FA period (53 patients), the mean age was 75 years (range, 54-86 years). All of the baseline characteristics were similar between the two different study periods. There were no significant differences between the two periods in the risk factors, medications, and lesion characteristics, which included symptomatic plaque, vulnerable plaque, and degree of stenosis according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET; Table I ).
RESULTS

Study population.
Effect of EPA and DHA administration. A day before CAS, triglyceride levels were significantly lower in the EPA and DHA period group (P < .01). EPA, DHA, EPA/ AA, and DHA/AA levels were significantly higher in the O-3FA period group a day before CAS (P < .01, P ¼ .02, P < .01, and P < .01, respectively; Table II ). In the O-3FA period group, total cholesterol, triglyceride, and lowdensity lipoprotein cholesterol levels were significantly decreased a day before CAS and 3 months after CAS compared with 4 weeks before CAS. High-density lipoprotein cholesterol levels were significantly increased 3 months after CAS compared with 4 weeks before CAS. Serum EPA and DHA levels and the EPA/AA and DHA/AA ratios were significantly increased a day before CAS and 3 months after CAS compared with 4 weeks before CAS.
CAS was performed successfully in all 100 patients (control period group, n ¼ 47; O-3FA period group, n ¼ 53) Closed-cell stents were used in 35 patients (75%) in the control period and 44 patients (83%) in the O-3FA period. A filter-type embolic protection device (FilterWire EZ) was used for all of the procedures in both groups. There was no significant difference in clopidogrel resistance between the two groups ( Table III ). There was no difference in re-treatment by percutaneous transmural angioplasty after CAS between the groups (Table III) . In symptomatic and asymptomatic subgroup analysis, there was a significant decrease in new ipsilateral ischemic lesions detected by DWI after CAS in symptomatic patients of the O-3FA group (P ¼ .03; Table IV ). In addition, on VH-IVUS analysis at the area of highest stenosis before stent placement, the fibrofatty area was significantly lower and the fibrous area was significantly higher in the O-3FA period (37.5 6 6.6 and 58.7 6 8.2, respectively) compared with the control period (50.4 6 8.9 [P < .01] and 44.0 6 11.8 [P < .01], respectively). In follow-up ultrasound examination performed 3, 6, and 12 months after CAS, PSV values of the ipsilateral internal carotid artery were not significantly different between the groups (Table V) 
DISCUSSION
In this study, O-3FA pretreatment reduced the slow-flow phenomenon generated by vulnerable plaque during CAS and ongoing daily use of O-3FA suppressed ISR 12 months after CAS in patients with hyperlipidemia receiving low-dose statin therapy. On multivariate logistic regression analysis, the serum EPA/AA ratio and the presence of a symptomatic lesion were the factors related to vulnerable plaque in patients undergoing CAS.
Stabilization of plaque vulnerability. It is well known that statin treatment stabilizes vulnerable carotid plaque for a minimum of 1 month, which is explained by the pleiotropic actions of statins, including improvements in endothelial function, decrease in the propensity for platelet thrombus formation, and reduction in inflammation at the site of the lesion. 7, 18 However, the exact mechanisms underlying this pathologic condition are not fully elucidated, and therefore the efficacy of potential therapies has been limited. In this study, although there were no significant differences in lesion characteristics, including the rate of vulnerable plaque, before O-3FA pretreatment between the groups, fibrofatty components at the area of highest stenosis before stent placement on VH-IVUS were significantly lower and the fibrous area was significantly higher in the O-3FA period group compared with the control period group. Furthermore, serum EPA and DHA levels and the EPA/AA and DHA/AA ratios were significantly increased a day before CAS compared with before O-3FA pretreatment, and a low EPA/AA ratio and symptomatic lesion were the factors related to vulnerable plaque on multivariate logistic regression analysis. These results suggest that EPA and DHA pretreatment may stabilize carotid plaque before CAS treatment. A clinical trial demonstrated that EPA reduced the incidence of recurrent stroke or coronary artery disease in the high-risk group. 19 Previous pathologic studies showed that a low serum EPA level and a low EPA/AA ratio were associated with high plaque vulnerability, and the addition of EPA in patients with dyslipidemia treated with statins was associated with a reduction in the lipid content of plaques in the coronary arteries as well as a decrease in inflammatory cytokines. 20, 21 Furthermore, a study has demonstrated that low serum DHA level is associated with progression of coronary atherosclerosis in statin-treated patients, suggesting that lipid-lowering therapy with O-3FAs added to statins is necessary to produce atheroma regression. 22 Gladine et al showed that supplementation with DHA during atherogenesis is associated with the production of oxygenated metabolites with reduced atherosclerosis progression. 23 These results are consistent with the present results that O-3FA pretreatment combined with statin therapy will stabilize carotid plaque before CAS treatment.
Effect of O-3FAs on the slow-flow phenomenon. In this study, we have used filter-type embolic protection devices because they are widely available and easy to use. They allow maintenance of anterograde carotid flow during the procedure and can reduce the incidence of hyperperfusion syndrome because they shorten the ischemia time in the ipsilateral hemisphere during CAS. During CAS with filter-type embolic protection devices, we have observed cases in which there is angiographic evidence of a significant reduction in antegrade flow in the internal carotid artery proximal to the filter device, termed slow flow. The mechanism of slow flow during CAS is supposed to be occlusion of the pores in the filter membrane, which is responsible for the impairment in antegrade flow, and the cause of the filter's clogging was amorphous material derived from the core of the atherosclerotic plaque, principally lipid-laden macrophages, cholesterol clefts, and fibrin material, determined histopathologically. 24 These plaque elements are extruded from the ruptured plaque on stent deployment and poststent balloon dilation. Therefore, the occurrence of the slow-flow phenomenon is associated with the composition and vulnerability of the carotid plaque. Although there was no significant difference in the number of vulnerable plaques between the groups before O-3FA pretreatment, the fibrofatty area was significantly lower and the fibrous area was significantly higher in the O-3FA period compared with the control period on VH-IVUS analysis. These results imply that EPA and DHA pretreatment improved plaque vulnerability and reduced the slow-flow phenomenon in this study. Indeed, filter-type embolic protection devices, type of stent, and degree of balloon angioplasty after stent placement also influence the frequency of the slowflow phenomenon during CAS. In this study, however, the same filter-type embolic protection devices were used in all CAS procedures, and there were no differences in the use of closed-cell stents between the groups. Furthermore, conservative postdilation to approximately 80% of the normal luminal diameter distal to the stenosis under IVUS measurement was performed in all CAS procedures. These results suggest that the difference in the frequency of the slow-flow phenomenon between the groups would be caused by the carotid plaque stabilization effect of O-3FA pretreatment. In contrast, in this study, there were no significant differences in ipsilateral ischemic lesions on DWI between the groups, even though slow flow is associated with the risk of ipsilateral periprocedural stroke. 24 It is possible that the aspiration techniques during the slow-flow phenomenon used in this study could prevent ipsilateral ischemic thromboembolism.
The effect of O-3FAs on ISR. ISR after CAS occurs frequently within the first year of follow-up and is associated with a higher risk of ischemic complications. The rates of ISR are as high as 20% in the literature, 25 and the development of ISR is secondary to hypersensitivity of neointimal hyperplasia, chronic inflammation, late malapposition related to positive remodeling, and delayed arterial healing with incomplete endothelialization. The risk factors for ISR have been identified and include factors such as advanced age, female sex, irradiated neck, prior revascularization, and insufficient dilation. 26 Histopathologic studies have shown that chronic inflammation and incompetent endothelial function are induced by neoatherosclerosis inside the stent, which may be an important mechanism of ISR. 27 In this study, ongoing daily use of O-3FAs after CAS significantly reduced ISR. EPA and DHA have been reported to have some beneficial effects on inflammation and oxidative stress. Cawood et al reported that higher carotid plaque EPA contents were associated with a reduced number of foam cells and T cells, and plaques from patients who received polyunsaturated fatty acids had significantly lower levels of messenger RNA for matrix metalloproteinases 7, 9, and 12 and for interleukin 6 and intercellular adhesion molecule 1, which indicated that atherosclerotic plaques readily incorporate EPA, and higher carotid plaque EPA contents are associated with reduced inflammation and increased stability. 13 In addition, Kelley et al found that DHA significantly reduced the number of circulating neutrophils, serum C-reactive protein level, and granulocyte-monocyte colony-stimulating factor and increased the concentration of matrix metalloproteinase 2, which indicated that DHA has anti-inflammatory effects. 28, 29 These results suggest that EPA and DHA may have a beneficial effect in reducing the incidence of ISR.
Limitations. This study has several limitations. First, the study design was a nonrandomized prospective trial with retrospective analysis of historical control data. Using historical control data may have introduced biases, and time periods are associated with improvements over time and therefore the study design may have influenced the present results. Furthermore, all CAS procedures were performed by experienced neurointerventionalists; however, other factors including the learning curve may have contributed to the results in the O-3FA period. Second, filter-type embolic protection devices may be inadequate to prevent migration of plaque fragments for vulnerable lesions with a lipid-rich necrotic core or intraplaque hemorrhage because a relatively high number of cases have shown a slow-flow phenomenon in the control period. More effective protection methods using flow reversal or flow stasis with occlusion of the external carotid artery and common carotid artery will be required for especially vulnerable carotid stenosis. Third, there were no symptomatic thromboembolic or hemorrhagic events in either group, and the incidence of re-treatment for ISR was not significant between the groups. The small sample size (limited power) and the relative short follow-up period may have introduced biases regarding the clinical benefits of O-3FA in preventing symptomatic thromboembolic complications and suppressing re-treatment for ISR. Further well-designed, randomized, controlled trials involving a larger number of patients are required to confirm the effect of pretreatment with and ongoing daily use of O-3FA on the clinical outcomes of patients after CAS.
CONCLUSIONS
Pretreatment with and ongoing use of O-3FA reduce the slow-flow phenomenon generated by plaque vulnerability during CAS and suppress ISR after CAS. 
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